Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

6.3K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
6.3K
The Ras Gene02:38

The Ras Gene

6.5K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.5K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

4.3K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.3K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

4.0K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
4.0K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.3K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.3K
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

10.1K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ATR inhibition activates cancer cell cGAS/STING-interferon signaling and promotes antitumor immunity in small-cell lung cancer.

Science advances·2024
Same author

Combination of MDM2 and Targeted Kinase Inhibitors Results in Prolonged Tumor Control in Lung Adenocarcinomas With Oncogenic Tyrosine Kinase Drivers and <i>MDM2</i> Amplification.

JCO precision oncology·2024
Same author

TGF-β and RAS jointly unmask primed enhancers to drive metastasis.

Cell·2024
Same author

Early Circulating Tumor DNA Shedding Kinetics for Prediction of Platinum Sensitivity in Patients With Small Cell Lung Cancer.

JCO precision oncology·2024
Same author

Chromothripsis-Mediated Small Cell Lung Carcinoma.

Cancer discovery·2024
Same author

Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity.

Trends in cancer·2024
Same journal

Biomolecular condensates for proteostasis and potential therapeutic applications.

Molecular cell·2026
Same journal

A negative regulator of mitochondrial complex I assembly adapts respiration to cellular energy demand.

Molecular cell·2026
Same journal

Large-scale tethered screen of RNA-binding proteins reveals novel regulators of poly(A) site selection.

Molecular cell·2026
Same journal

Longitudinal monitoring of cytoplasmic RBP-RNA interactions and transcriptome in living cells by engineered protein nanocages.

Molecular cell·2026
Same journal

Structures of the PI3Kα/KRas complex on lipid bilayers reveal molecular mechanisms of PI3Kα activation.

Molecular cell·2026
Same journal

Oligomer disassembly activates an HEPN-containing bacterial defense system.

Molecular cell·2026
See all related articles

Related Experiment Video

Updated: Sep 22, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K

ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1.

Wenjing Su1, Radha Mukherjee1, Rona Yaeger2

  • 1Molecular Pharmacology Program, Sloan Kettering Institute for Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Molecular Cell
|May 25, 2022
PubMed
Summary
This summary is machine-generated.

ARAF protein activates RAS independently of its kinase function by displacing NF1, prolonging RAS signaling. This mechanism contributes to tumor cell growth and resistance to EGFR inhibitors in lung cancer.

Keywords:
ARAFERK signalingNF1RAS-GTPdrug sensitivityreceptor tyrosine kinase inhibitor

More Related Videos

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.2K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.1K

Related Experiment Videos

Last Updated: Sep 22, 2025

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

6.2K
Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells
06:44

Author Spotlight: Integrating BRET-Based Assays and Rare Mutation Analysis to Decipher RAF Kinase Regulation in Live Cells

Published on: March 1, 2024

1.2K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

3.1K

Area of Science:

  • Molecular biology
  • Cell signaling
  • Oncology

Background:

  • RAF kinases are effectors of RAS (small guanosine triphosphatase) and phosphorylate MEK.
  • RAS-GTP activates downstream signaling pathways, including the ERK pathway, which is crucial for cell proliferation and survival.
  • Dysregulation of RAS signaling is implicated in various cancers, including lung cancer.

Purpose of the Study:

  • To investigate the kinase-independent function of ARAF in RAS activation.
  • To elucidate the mechanism by which ARAF regulates RAS signaling.
  • To explore the role of ARAF in acquired resistance to EGFR inhibitors in lung cancer.

Main Methods:

  • Expression of ARAF in cells.
  • Assessing RAS activation through GTP-bound RAS levels.
  • Investigating the interaction between ARAF, RAS, and NF1 using co-immunoprecipitation.
  • Evaluating the effect of ARAF on ERK-dependent signaling.
  • Analyzing ARAF amplification in lung cancer patient samples and its correlation with treatment resistance.

Main Results:

  • ARAF expression activated RAS in a kinase-independent manner.
  • ARAF binding to RAS displaced the GTPase-activating protein NF1.
  • This displacement antagonized NF1-mediated RAS inhibition, leading to increased RAS-GTP levels.
  • ARAF regulated the duration and consequences of RTK-induced RAS activation.
  • ARAF amplification correlated with acquired resistance to EGFR inhibitors in lung cancers with EGFR mutations.
  • Combining EGFR inhibitors with SHP2 inhibitors overcame this resistance.

Conclusions:

  • ARAF possesses a kinase-independent function that activates RAS by antagonizing NF1.
  • This mechanism contributes to RTK-induced RAS activation and supports tumor cell growth.
  • ARAF amplification is a mechanism of acquired resistance to EGFR inhibitors in lung cancer, which can be overcome by SHP2 inhibition.